The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Angiotensin II Type 1 Receptor Blockers
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., & Smith, R. D. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00446-6 · Cited by 1,853
Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665
Essential Hypertension: Renin and Aldosterone, Heart Attack and Stroke
Brunner, H. R., Laragh, J. H., Baer, L., Newton, M. A., Goodwin, F. T., Krakoff, L. R., Bard, R. H., & Bühler, F. R. (1972) · New England Journal of Medicine · doi:10.1056/nejm197203022860901 · Cited by 1,093
Stoll, M., Steckelings, U. M., Paul, M., Bottari, S. P., Metzger, R., & Unger, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117710 · Cited by 906
Urata, H., Kinoshita, A., Misono, K. S., Bumpus, F. M., & Husain, A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45712-2 · Cited by 880
Mukoyama, M., Nakajima, M., Horiuchi, M., Sasamura, H., Pratt, R. E., & Dzau, V. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74498-6 · Cited by 768
Kambayashi, Y., Bardhan, S., Takahashi, K., Tsuzuki, S., Inui, H., Hamakubo, T., & Inagami, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74499-8 · Cited by 714
Plasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Nakajima, M., Hutchinson, H. G., Fujinaga, M., Hayashida, W., Morishita, R., Zhang, L., Horiuchi, M., Pratt, R. E., & Dzau, V. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10663 · Cited by 680
Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz, W., Wiemer, G., Gohlke, P., Unger, T., & Schölkens, B. A. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06820-6 · Cited by 650
Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man
Gavras, H., Brunner, H. R., Turini, G. A., Kershaw, G. R., Tifft, C. P., Cuttelod, S., Gavras, I., Vukovich, R. A., & McKinstry, D. N. (1978) · New England Journal of Medicine · doi:10.1056/nejm197805042981803 · Cited by 602
Gainer, J. V., Morrow, J. D., Loveland, A., King, D. J., & Brown, N. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810293391804 · Cited by 443
Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.
Nio, Y., Matsubara, H., Murasawa, S., Kanasaki, M., & Inada, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117675 · Cited by 435
Angiotensin II Type 1a Receptor-deficient Mice with Hypotension and Hyperreninemia
Sugaya, T., Nishimatsu, S.-I., Tanimoto, K., Takimoto, E., Yamagishi, T., Imamura, K., Goto, S., Imaizumi, K., Hisada, Y., Otsuka, A., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18719 · Cited by 366
Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients
BRUNNER, H. R., GAVRAS, H., WAEBER, B., KERSHAW, G. R., TURINI, G. A., VUKOVICH, R. A., McKINSTRY, D. N., & GAVRAS, I. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-1-19 · Cited by 356
Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
Lafayette, R. A., Mayer, G., Park, S. K., & Meyer, T. W. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115949 · Cited by 348
Siragy, H. M., & Carey, R. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118630 · Cited by 314
Gansevoort, R. T., de Zeeuw, D., & de Jong, P. E. (1994) · Kidney International · doi:10.1038/ki.1994.113 · Cited by 292
Losartan in Heart Failure: Hemodynamic Effects and Tolerability
Crozier, I., Ikram, H., Awan, N., Cleland, J., Stephen, N., Dickstein, K., Frey, M., Young, J., Klinger, G., Makris, L., et al. (1995) · Circulation · doi:10.1161/01.cir.91.3.691 · Cited by 291
Gottlieb, S. S., Dickstein, K., Fleck, E., Kostis, J., Levine, T. B., LeJemtel, T., & DeKock, M. (1993) · Circulation · doi:10.1161/01.cir.88.4.1602 · Cited by 291
Gavras, H., Brunner, H. R., Vaughan, E. D., & Laragh, J. H. (1973) · Science · doi:10.1126/science.180.4093.1369 · Cited by 289
Goldberg, A. I., Dunlay, M. C., & Sweet, C. S. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80413-5 · Cited by 270
Ohkubo, N., Matsubara, H., Nozawa, Y., Mori, Y., Murasawa, S., Kijima, K., Maruyama, K., Masaki, H., Tsutumi, Y., Shibazaki, Y., et al. (1997) · Circulation · doi:10.1161/01.cir.96.11.3954 · Cited by 246
Christen, Y., Waeber, B., Nussberger, J., Porchet, M., Borland, R. M., Lee, R. J., Maggon, K., Shum, L., Timmermans, P. B., & Brunner, H. R. (1991) · Circulation · doi:10.1161/01.cir.83.4.1333 · Cited by 244
Russo, D., Pisani, A., Balletta, M. M., De Nicola, L., Savino, F. A., Andreucci, M., & Minutolo, R. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70416-6 · Cited by 243
Brunner, H. R., Gavras, H., Laragh, J. H., & Keenan, R. (1973) · The Lancet · doi:10.1016/s0140-6736(73)92657-3 · Cited by 241
Linz, W., & Schölkens, B. A. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb09054.x · Cited by 236
The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells
Meffert, S., Stoll, M., Steckelings, U. M., Bottari, S. P., & Unger, T. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(96)03873-7 · Cited by 229
Gradman, A. H., Arcuri, K. E., Goldberg, A. I., Ikeda, L. S., Nelson, E. B., Snavely, D. B., & Sweet, C. S. (1995) · Hypertension · doi:10.1161/01.hyp.25.6.1345 · Cited by 226
Azizi, M., Chatellier, G., Guyene, T.-T., Murieta-Geoffroy, D., & Ménard, J. (1995) · Circulation · doi:10.1161/01.cir.92.4.825 · Cited by 217
Effects of modulators of the renin???angiotensin???aldosterone system on cough
Lacourci??re, Y., Brunner, H., Irwin, R., Karlberg, B. E., Ramsay, L. E., Snavely, D. B., Dobbins, T. W., Faison, E. P., & Nelson, E. B. (1994) · Journal of Hypertension · doi:10.1097/00004872-199412000-00012 · Cited by 216
Role of angiotensin subtype 2 receptor in neointima formation after vascular injury.
Janiak, P., Pillon, A., Prost, J. F., & Vilaine, J. P. (1992) · Hypertension · doi:10.1161/01.hyp.20.6.737 · Cited by 213
Hamroff, G., Katz, S. D., Mancini, D., Blaufarb, I., Bijou, R., Patel, R., Jondeau, G., Olivari, M.-T., Thomas, S., & Le Jemtel, T. H. (1999) · Circulation · doi:10.1161/01.cir.99.8.990 · Cited by 212
Baruch, L., Anand, I., Cohen, I. S., Ziesche, S., Judd, D., & Cohn, J. N. (1999) · Circulation · doi:10.1161/01.cir.99.20.2658 · Cited by 202
Harada, K., Sugaya, T., Murakami, K., Yazaki, Y., & Komuro, I. (1999) · Circulation · doi:10.1161/01.cir.100.20.2093 · Cited by 201
Thürmann, P. A., Kenedi, P., Schmidt, A., Harder, S., & Rietbrock, N. (1998) · Circulation · doi:10.1161/01.cir.98.19.2037 · Cited by 196
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
Burnier, M., Rutschmann, B., Nussberger, J., Versaggi, J., Shahinfar, S., Waeber, B., & Brunner, H. R. (1993) · Hypertension · doi:10.1161/01.hyp.22.3.339 · Cited by 195
Self-citationDickstein, K., Chang, P., Willenheimer, R., Haunsø, S., Remes, J., Hall, C., & Kjekshus, J. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)80020-h · Cited by 194
IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRIL
Turini, G., Brunner, H., Gribic, M., Waeber, B., & Gavras, H. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91897-x · Cited by 181
Kassler-Taub, K. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00491-3 · Cited by 168
Cloning and characterization of a human angiotensin II type 1 receptor
Bergsma, D. J., Ellis, C. E., Kumar, C. S., Nuthulaganti, P., Kersten, H., Elshourbagy, N. A., Griffin, E., Stadel, J. M., & Aiyar, N. V. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80288-8 · Cited by 148
MacKay, J. H., Arcuri, K. E., Goldberg, A. I., Snapinn, S. M., & Sweet, C. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440030072009 · Cited by 147
Ots, M., Mackenzie, H. S., Troy, J. L., Rennke, H. G., & Brenner, B. M. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v92224 · Cited by 146
Corea, L., Cardoni, O., Fogari, R., Innocenti, P., Porcellati, C., Provvidenza, M., Meilenbrock, S., Sullivan, J., & Bodin, F. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90061-2 · Cited by 133
Angioneurotic Edema Attributed to the Use of Losartan
van Rijnsoever, E. W., Kwee-Zuiderwijk, W. J., & Feenstra, J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.18.2063 · Cited by 126
Holwerda, N. J., Fogari, R., Angeli, P., Porcellati, C., Hereng, C., Oddou-Stock, P., Heath, R., & Bodin, F. (1996) · Journal of Hypertension · doi:10.1097/00004872-199609000-00016 · Cited by 124
Black, H., Graff, A., Shute, D., et al. (1997) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000482 · Cited by 120
Tikkanen, I., Omvik, P., & Ekblad, H. (1995) · Journal of Hypertension · doi:10.1097/00004872-199511000-00017 · Cited by 115
Effect of AT2receptor blockade on the pathogenesis of renal fibrosis
Morrissey, J. J., & Klahr, S. (1999) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1999.276.1.f39 · Cited by 112
Combination ACE Inhibitor and Angiotensin II Receptor Antagonist Therapy in Diabetic Nephropathy
Hebert, L. A., Falkenhain, M. E., Nahman, N. S., Cosio, F. G., & O’Dorisio, T. M. (1999) · American Journal of Nephrology · doi:10.1159/000013417 · Cited by 110
Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril.
Bao, G., Gohlke, P., Qadri, F., & Unger, T. (1992) · Hypertension · doi:10.1161/01.hyp.20.1.74 · Cited by 108
Renal effects of angiotensin II receptor blockade in normotensive subjects
Burnier, M., Roch‐Ramel, F., & Brunner, H. R. (1996) · Kidney International · doi:10.1038/ki.1996.268 · Cited by 107
Self-citationBenz, J. R., Oshrain, C., Henry, D. C., Avery, C., Chiang, Y., & Gatlin, M. R. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04767.x · Cited by 104
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy
Remuzzi, A., Perico, N., Sangalli, F., Vendramin, G., Moriggi, M., Ruggenenti, P. L., & Remuzzi, G. (1999) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1999.276.3.f457 · Cited by 104
Dahlöf, B., Keller, S. E., Makris, L., et al. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00081-y · Cited by 102
Dzau, V. J., Sasamura, H., & Hein, L. (1993) · PubMed · Cited by 102
Angiotensin II Receptor Blockade in Normotensive Subjects
Mazzolai, L., Maillard, M. P., Rossat, J., Nussberger, J., Brunner, H. R., & Burnier, M. (1999) · Hypertension · doi:10.1161/01.hyp.33.3.850 · Cited by 96
Self-citationCharacterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy Volunteers
Delacrétaz, E., Nussberger, J., Biollaz, J., Waeber, B., & Brunner, H. R. (1995) · Hypertension · doi:10.1161/01.hyp.25.1.14 · Cited by 93
Effects of AT 1 and AT 2 Angiotensin Receptor Antagonists in Angiotensin II-Infused Rats
Li, J. S., Touyz, R. M., & Schiffrin, E. L. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.487 · Cited by 93
Comparative Safety and Tolerability of Angiotensin II Receptor Antagonists
Mazzolai, L., & Burnier, M. (1999) · Drug Safety · doi:10.2165/00002018-199921010-00003 · Cited by 92
Self-citationDose-Related Efficacy of Irbesartan for Hypertension: An Integrated Analysis
Reeves, R. A., Lin, C.-S., Kassler-Taub, K., & Pouleur, H. G. (1998) · Hypertension · doi:10.1161/01.hyp.31.6.1311 · Cited by 92
Short-term and Sustained Renal Effects of Angiotensin II Receptor Blockade in Healthy Subjects
Burnier, M., Hagman, M., Nussberger, J., Biollaz, J., Armagnac, C., Brouard, R., Waeber, B., & Brunner, H. R. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.602 · Cited by 92
Self-citationOparil, S., Guthrie, R. M., Lewin, A. J., Marbury, T. C., Reilly, K., Triscari, J. M., & Witcher, J. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80051-9 · Cited by 90
Mimran, A., Ruilope, L. M., Kerwin, L. J., Nys, M., Owens, D., Kassler-Taub, K., & Osbakken, M. D. (1998) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000591 · Cited by 88
Plum, J., Bünten, B., Németh, R., & Grabensee, B. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9122223 · Cited by 83
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions
Willenheimer, R. B. (1999) · European Heart Journal · doi:10.1053/euhj.1999.1547 · Cited by 83
Role of Angiotensin Receptor Subtypes in Mesenteric Vascular Proliferation and Hypertrophy
Cao, Z., Dean, R. G., Wu, L. L., CASLEY, D. J., & Cooper, M. E. (1999) · Hypertension · doi:10.1161/01.hyp.34.3.408 · Cited by 75
YChristen, BWaeber, JNussberger, et al. (1991) · Circulation · Cited by 75
Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
Müller, P., Cohen, T., de Gasparo, M., Sioufi, A., Bacine-Poon, A., & HOWALD, H. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf02570503 · Cited by 74
Péchère-Bertschi, A., Nussberger, J., Decosterd, L. A., Armagnac, C., Sissmann, J., Bouroudian, M., Brunner, H. R., & Burnier, M. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816030-00016 · Cited by 73
Self-citationPerico, N., Remuzzi, A., Sangalli, F., Azzollini, N., Mister, M., Ruggenenti, P. L., & Remuzzi, G. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9122308 · Cited by 73
Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
Havranek, E. P., Thomas, I., Smith, W. B., Ponce, G. A., Bilsker, M., Munger, M. A., & Wolf, R. A. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00695-0 · Cited by 64
Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours
Neutel, J., Weber, M. A., Pool, J. L., Smith, D., Fitzsimmons, S., Chiang, Y., & Gatlin, M. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80129-4 · Cited by 57
Converting enzyme inhibition in kinin-deficient brown Norway rats.
Danckwardt, L., Shimizu, I., Bönner, G., Rettig, R., & Unger, T. (1990) · Hypertension · doi:10.1161/01.hyp.16.4.429 · Cited by 57
Weir, M. R., Elkins, M., Liss, C. L., Vrecenak, A. J., Barr, E., & Edelman, J. M. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80022-1 · Cited by 55
Bremner, A., Baur, M., Oddou-Stock, P., & Bodin, F. (1997) · Clinical and Experimental Hypertension · doi:10.3109/10641969709083217 · Cited by 54
Prevention of Renal Injury in Diabetic MWF Rats by Angiotensin II Antagonism
Remuzzi, A., Fassi, A., Sangalli, F., Malanchini, B., Mohamed, E. I., Bertani, T., & Remuzzi, G. (1998) · Nephron Experimental Nephrology · doi:10.1159/000020502 · Cited by 41
Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition
Bouaziz, H., Joulin, Y., Safar, M. E., & Bénétos, A. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb17052.x · Cited by 40
Valsartan and atenolol in patients with severe essential hypertension
Cífková, R., Peleška, J., Hradec, J., et al. (1998) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000615 · Cited by 32
Clinical Efficacy of Eprosartan
Weber, M. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.7.95s.30950 · Cited by 14
Cited by
Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
Brooke, B. S., Habashi, J. P., Judge, D. P., Patel, N., Loeys, B., & Dietz, H. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706585 · Cited by 843
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Flora, G. D., & Nayak, M. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190925163827 · Cited by 476
Groenink, M., den Hartog, A. W., Franken, R., Radonic, T., de Waard, V., Timmermans, J., Scholte, A. J., van den Berg, M. P., Spijkerboer, A. M., Marquering, H. A., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht334 · Cited by 396
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
Metadata
- Authors
- Burnier, M.
- Venue
- Circulation
- Published
- 2001-02-13
- Volume
- 103
- Issue
- 6
- Pages
- 904-912
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2159729565
- Cited by
- 485
- References
- 86
- FWCI
- 22.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.